We selected the Trastuzumab (TZ) antibody as a recognition element because it targets and binds HER2, inhibits the signalling pathways that promote cell growth, helping to restrain the uncontrolled growth of cancer cells [39, 40]. Here, ERBB2 is linked to cancer.